Project Grant HT94252310241
Award Date
9/1/23
Completion Date
8/31/25
Dollars Obligated
$409K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Boston, MA 02114, USA
Similar Awards
The Defense Health Agency awarded a $732,825 Project Grant to The General Hospital Corporation (Massachusetts General Hospital) under the Military Medical Research and Development program (CFDA 12.420) for an extension of an artificial chromosome-based system as a novel delivery strategy for CAR-T cell therapy of ovarian cancer to human lymphocytes. This 3-year project, running from September 1, 2023 to August 31, 2026, aims to develop and validate new treatment approaches for ovarian cancer. As...
This Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) provides $730,033 to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), for research to develop therapies targeting AMH signaling within the ovarian cancer tumor microenvironment. The award has a performance period from April 15, 2024 to April 14, 2027. As part of its extensive biomedical research portfolio,...
This $1,234,505 federal Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) supports the General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), in conducting research to revolutionize antibody-drug conjugate therapy for refractory breast cancers. The research project, titled "Cotargeting the Tumor Microenvironment to Revolutionize Antibody-Drug Conjugate Therapy for...
The Department of the Army Medical Command awarded a $781,530 Project Grant to the Massachusetts General Hospital through the Military Medical Research and Development program. The grant will fund research from February 2021 to January 2024 to develop precision antibody-based synergistic drug combinations for refractory triple-negative breast cancer. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goals of improving...
The Massachusetts General Hospital was awarded a $930,660 project grant from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program (CFDA 12.420) to conduct a pilot randomized trial evaluating minimally invasive surgery for advanced ovarian cancer. The goal of the trial is to investigate medical solutions for ovarian cancer treatment through the support of applied biomedical research. Dr. Rauh-Hain of Massachusetts General Hospital...
The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), was awarded a $577,094 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research aimed at "Redirecting Viral Immunity to Eradicate Low Tumor Mutation Burden Lung Cancers." The award period runs from Aug 31, 2023 to Aug 29, 2025. As a leading academic medical center and research institution, MGH utilizes its...
The Massachusetts General Hospital will receive $826,584 under a three-year Project Grant award from the Department of the Army Medical Command's Military Medical Research and Development program. The grant will fund research into the mechanisms mediating the immune response after proton versus photon radiotherapy in IDH-mutant liver cancer. The study aims to investigate medical solutions for the battlefield and transform health care for service members and the public through innovative...
The Defense Health Agency awarded a $1,621,712 Project Grant to The General Hospital Corporation's Research Management Division, operating as Massachusetts General Hospital (MGH), for the "THERAPEUTIC TARGETING OF CHEMORESISTANT RHABDOMYOSARCOMA" project. This award is funded through the Military Medical Research and Development program (CFDA 12.420), which supports a range of biomedical research initiatives to improve health outcomes for military service members, veterans, and the...
This federal Project Grant award, valued at $1,498,368.00 and issued by the Defense Health Agency, supports research conducted by The General Hospital Corporation (doing business as Massachusetts General Hospital) under the Military Medical Research and Development (CFDA 12.420) program. The research aims to elucidate the molecular mechanisms of tumor-immune dynamics and evolution in response to radiation, with the goal of optimizing treatment for high- and very high-risk prostate cancer. The...
The Defense Health Agency awarded Dana-Farber Cancer Institute a $1,046,135 project grant under the Military Medical Research and Development program to conduct research titled "Drugging the Undruggable: Programming Ovarian Cancer Cells as the Next-Generation Immunotherapy." The three-year award runs from May 15, 2023 to May 14, 2026. As the prime recipient, Dana-Farber will leverage its expertise in tumor biology, immunology and drug development to research new therapies for ovarian...